{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:08:08Z","timestamp":1795043288919,"version":"4.10.2"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010438","name":"Francis Crick Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.antiviral.2020.104718","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T15:57:46Z","timestamp":1580227066000},"page":"104718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"special_numbering":"C","title":["Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017\u20132018"],"prefix":"10.1016","volume":"175","author":[{"given":"Emi","family":"Takashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod S.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa V.","family":"Gubareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Lackenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Pereyaslov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104718_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1086\/595736","article-title":"A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A\/H3N2 virus","volume":"199","author":"Abed","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104718_bib2","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02628-13","article-title":"Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y","volume":"58","author":"Burnham","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104718_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2012.10.095","article-title":"A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs","volume":"429","author":"Fujisaki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2020.104718_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016","volume":"146","author":"Gubareva","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib5","first-page":"337","article-title":"Baloxavir and treatment-emergent resistance: public Health insights and next steps","volume":"221","author":"Gubareva","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104718_bib6","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104718_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104718_bib8","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","author":"Hirotsu","year":"2019","journal-title":"Clin. Infect. Dis.\u202f: Offc. Publ. Infect. Dis. Soc. Am"},{"key":"10.1016\/j.antiviral.2020.104718_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2016.06.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015","volume":"132","author":"Hurt","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virusres.2004.02.035","article-title":"Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs","volume":"103","author":"Hurt","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41564-019-0609-0","article-title":"Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets","volume":"5","author":"Imai","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104718_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.02.007","article-title":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018","volume":"164","author":"Koszalka","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib14","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30060","article-title":"Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring","volume":"20","author":"Little","year":"2015","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104718_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013","volume":"110","author":"Meijer","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1086\/656439","article-title":"Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y\/I223R mutation from a child after prolonged treatment with oseltamivir","volume":"51","author":"Nguyen","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104718_bib17","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104718_bib18","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3201\/eid2511.190757","article-title":"Human-to-Human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, february 2019","volume":"25","author":"Takashita","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104718_bib19","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104718_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.02.003","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014","volume":"117","author":"Takashita","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104718_bib21","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3389\/fmicb.2018.03026","article-title":"Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil","volume":"9","author":"Takashita","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104718_bib22","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1128\/AAC.04939-14","article-title":"Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses","volume":"59","author":"Tamura","year":"2015","journal-title":"Antimicrob. Agents Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104718_bib23","first-page":"346","article-title":"Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza","volume":"221","author":"Uehara","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104718_bib24","first-page":"369","article-title":"Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - geneva, November 2011 and June 2012","volume":"87","author":"Who","year":"2012","journal-title":"Wkly. Epidemiol. Rec."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219306370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219306370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:30:43Z","timestamp":1759062643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219306370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"alternative-id":["S0166354219306370"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104718","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017\u20132018","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104718"}}